NASDAQ · MASSHealthcareLab Analytical Instruments

908 Devices financials

$11.85+1.63%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$56.2M$47.7M$50.2M$46.9M$42.2M$26.9M
Gross profit$28.4M$24.5M$25.3M$26.0M$23.2M$14.9M
Gross margin50.6%51.3%50.4%55.5%55.0%55.5%
Operating income-$39.4M-$57.4M-$42.8M-$35.4M-$22.1M-$5.8M
Net income$19.5M-$72.2M-$36.4M-$33.6M-$22.2M-$12.9M
Net margin34.7%−151.2%−72.5%−71.6%−52.5%−48.0%
Diluted EPS$0.54$-2.12$-1.13$-1.07$-0.79$-2.35
EBITDA-$35.0M-$12.1M-$40.4M-$33.8M-$21.1M-$5.0M
Operating cash flow-$23.7M-$30.2M-$25.1M-$20.9M-$29.1M$4.1M
Free cash flow-$24.6M-$30.8M-$27.1M-$23.0M-$29.8M$4.1M
Diluted shares35.9M34.1M32.2M31.5M28.0M5.5M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$70.5M$43.4M$121.0M$188.4M$224.1M$159.2M
Short-term investments$42.5M$25.6M$24.6M$0.00——
Total debt$0.00$0.00$0.00$15.0M$15.0M$14.8M
Total assets$190.1M$159.5M$203.0M$242.6M$260.9M$178.8M
Total liabilities$46.4M$44.9M$37.5M$52.0M$46.3M$39.8M
Shareholders' equity$143.7M$114.6M$165.5M$190.6M$214.6M$139.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology